Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H41NO2 |
| Molecular Weight | 327.545 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCC(=O)NCCO
InChI
InChIKey=OTGQIQQTPXJQRG-UHFFFAOYSA-N
InChI=1S/C20H41NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h22H,2-19H2,1H3,(H,21,23)
Stearic monoethanolamide (widely known as N-stearoylethanolamine, NSE) is a biologically active cell membrane component with anti-inflammatory and membrane-protective properties. Preliminary data from a model of experimental burn in rats have shown that N-stearoylethanolamine externally applied has an anti-inflammatory effect. A significant decrease of cytokines (IL-1beta, IL-6, and TNF-alpha) levels under the NSE action, it could be one of the mechanisms of its anti-inflammatory action. The large increase in the level of N-stearoylethanolamine in myalgic muscles may reflect an attempt by the body to counteract noxious processes and activation of nociceptors because of the myalgia. If this is the case, then compound preventing their breakdown N-stearoylethanolamine may be useful analgesics for this indication. In addition, recently was studied the therapeutic potential of NSE for prevention of cognitive disfunction caused by neuroinflammation or autoimmune reaction that allowed suggesting this drug as a candidate for the treatment or prophylaxis of Alzheimer's pathology.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P01584 Gene ID: 3553.0 Gene Symbol: IL1B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25033558 |
|||
Target ID: P05231 Gene ID: 3569.0 Gene Symbol: IL6 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25033558 |
|||
Target ID: P01375 Gene ID: 7124.0 Gene Symbol: TNF Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25033558 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19873884 |
Palliative | Unknown Approved UseUnknown |
||
| Diagnostic | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Inactive ingredient | Nu Skin Nu Colour Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. | 2010-07 |
|
| Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women. | 2010-06-14 |
|
| Genetic manipulation of palmitoylethanolamide production and inactivation in Saccharomyces cerevisiae. | 2009-06-16 |
|
| Synthesis and anticonvulsant activity of N-(2-hydroxy-ethyl)amide derivatives. | 2009-01 |
|
| A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story... | 2008-05 |
|
| Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. | 2008-04 |
|
| Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. | 2006-03 |
|
| Effects of saturated long-chain N-acylethanolamines on voltage-dependent Ca2+ fluxes in rabbit T-tubule membranes. | 2005-02-15 |
|
| Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver stearoyl-coenzyme A desaturase-1 mRNA expression. | 2004-10 |
|
| Cannabinoid CB1 receptor activation does not prevent the toxicity of glutamate towards embryonic chick telencephalon primary cultures. | 2003-11 |
|
| Cannabimimetic activity, binding, and degradation of stearoylethanolamide within the mouse central nervous system. | 2002-09 |
|
| Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. | 2002-08-15 |
|
| Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. | 2001-09-21 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19873884
burn injury in rats: the animals after the thermal burn of the skin received per os during 7 days the water suspension of N-stearoylethanolamine (NSE) in a doze 10 mg/kg of body weight.
Route of Administration:
Transdermal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25997585
It was estimated the effect of N-Stearoylethanolamine (NSE, STEARIC MONOETHANOLAMIDE) on inflammatory cytokines mRNA level (leukemia cells L1210), cytokines content (serum and LPS-stimulated macrophages) and nuclear translocation of NF-κB (peritoneal macrophages LPS-stimulated and isolated from rats with obesity-induced insulin resistance). The results indicated that NSE dose-dependently inhibits the IL-1 and IL-6 mRNA level in L1210 cells. Furthermore, the NSE treatment triggered a normalization of serum TNF-α level in insulin resistant rats and a reduction of medium IL-1 level in LPS-activated peritoneal macrophages.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Stearoylethanolamide
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY | |||
|
03XV449Q24
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY | |||
|
1426353
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY | RxNorm | ||
|
85299
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY | |||
|
203-883-2
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY | |||
|
DTXSID9042178
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY | |||
|
03XV449Q24
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY | |||
|
3377
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY | |||
|
111-57-9
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY | |||
|
27902
Created by
admin on Mon Mar 31 18:01:54 GMT 2025 , Edited by admin on Mon Mar 31 18:01:54 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD